Loren Data's SAM Daily™

FBO DAILY ISSUE OF JANUARY 20, 2005 FBO #1151
SOLICITATION NOTICE

A -- Preclinical Study of Efficacy in Animal Models of Type 1 Diabetes

Notice Date

1/18/2005
 

Notice Type

Solicitation Notice
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W 6707 Democracy Blvd., MSC 5455, Bethesda, MD, 20892-5455
 

ZIP Code

20892-5455
 

Solicitation Number

NIH-NIDDK-05-05
 

Response Due

5/6/2005
 

Archive Date

5/21/2005
 

Description

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) is seeking an organization or an institution to perform preclinical studies of potential new therapeutics for the prevention or treatment of type 1 diabetes. A clinical evaluation is not desired at this time. The Contractor will work closely with NIDDK project staff and external scientific consultants in designing protocols appropriate for the individual requirements of these compounds. The Contractor shall prepare draft protocols with the final design to be agreed to by the Project Officer. The Contractor shall conduct studies of potential new therapeutics for the treatment and prevention of type 1 diabetes as agreed to by the Project Officer. The Contractor shall prepare final study reports in consultation with the Project Officer for submission as Investigational New Drug applications (IND) to the Food and Drug Administration (FDA) for support of efficacy and /or mechanism of action of the potential new therapeutic. A contract has not been awarded previously for these services. The Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) program is designed to assist translation from the research bench to the clinic of novel therapeutic interventions for Type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program (NCI DTP). The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.
 

Place of Performance

Address: 6707 Democracy Blvd., Rm. 779, Bethesda, MD

Zip Code: 20817

Country: USA
 

Record

SN00736047-W 20050120/050118211633 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |